SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users promote the coin and its association with cannabis culture. The community emphasizes the coin's cultural significance, steady growth, and resilience. Some users are also speculating about potential upcoming catalysts such as a CMC listing.

KULR Technology Group, Inc. engages in developing, manufacturing, and licensing next-generation carbon fiber thermal management technologies for batteries and electronic systems. Its products include cellcheck, safecase, thermal capacitor, fiber thermal interface, thermal runaway shield, internal short circuit, and cathode. The company was founded by Michael Mo and Timothy R. Knowles in December 2015 and is headquartered in Webster, TX.

KULR Technology Group Inc

KULR is trending due to a surge in volume and community discussion around its Thursday's kBMS launch for defense and space. Bullish sentiment is building, with some eyeing a potential short squeeze and upside to the $7 level. The company's Bitcoin holdings and thermal runaway technology are also being discussed as potential drivers.

GME Ethereum

GME Ethereum is trending as the community anticipates a potential "god candle" and a tweet from Roaring Kitty, sparking excitement. Conversations revolve around potential catalysts and the overall bullish sentiment surrounding the coin. Some community members highlight locked liquidity and a "savage" team as reasons for optimism, while others suggest that it is a scam.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors discuss the company's potential as an AI acquisition target, particularly after recent activity in the data labeling space. Community members are analyzing INOD's recruitment strategies, financial positioning, and technical indicators, interpreting them as signs of a potential takeover or significant new contracts. Bullish sentiment prevails, with focus shifting towards potential short squeezes and price targets.

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARKG is gaining attention as investors discuss potential breakout patterns and compare its performance to other ARK funds, with some expressing frustration over its historical returns. Community members are actively debating entry points and speculating on future catalysts, particularly the impact of AI on genomic advancements. Despite mixed sentiment regarding management, there's anticipation for a potential sector-wide upswing and the impact of future rate cuts.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending as investors discuss the upcoming October 7th shareholder vote regarding its merger with Terra Innovatum, anticipating a ticker change to NKLR. Community talking points include the company's potential in the nuclear energy sector, especially in micro-modular reactors, and comparisons to peers like OKLO and SMR, highlighting potential undervaluation. The focus remains on the merger's completion and the subsequent impact on the stock's price.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF ($BTC) is trending as Bitcoin flirts with all-time highs, sparking discussions about its potential as a safe haven asset amidst government shutdowns. The community highlights potential breakouts and retracements, with some eyeing specific price levels and scaling strategies for call options. Community members are also closely watching MicroStrategy ($MSTR) relative to Bitcoin's gains.

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Prime Medicine Inc

Prime Medicine is trending as the stock experiences increased interest, potentially driven by bullish options activity and renewed excitement around the gene editing space. Community members are actively discussing the company's potential in curing rare diseases and speculating on possible institutional or insider buying. Some investors believe the current administration's focus on healthcare and gene editing could further boost Prime Medicine's prospects.

First Horizon Corp. (Tennessee) operates as a financial holding company, which engages in the provision of checking accounts, savings products, mortgage banking, lending, and financing to individuals and businesses. It operates the business through three segments: Regional Banking, Specialty Banking, and Corporate. The Regional Banking segment offers financial products and services, including traditional lending and deposit taking, to retail and commercial customers. The Specialty Banking segment consists of lines of business that deliver product offerings and services with specialized industry knowledge. The Corporate segment focuses on corporate support functions such as risk management, audit, accounting, finance, executive office, and corporate communications. The company was founded by Frank S. Davis in 1864 and is headquartered in Memphis, TN.

First Horizon Corporation

First Horizon is trending due to the collapse of its merger agreement with TD Bank, leading to a significant stock plunge. While some view this as an overreaction and a buying opportunity, others are concerned about the bank's future prospects amid broader regional banking sector instability. Community discussion revolves around potential acquisitions, the bank's financial health, and the impact of the failed merger.

Vulcan Materials Co. engages in the production of construction aggregates. It operates through the following segments: Aggregates, Asphalt, and Concrete. The Aggregates segment produces and sells aggregates and related products and services. The Asphalt segment relates to the production and selling of asphalt mix in Arizona, California, New Mexico, Tennessee, and Texas. The Concrete segment refers to the production and selling of ready-mixed concrete in California, Maryland, and Virginia in addition to the U.S. Virgin Islands and Washington D.C. The company was founded in 1909 and is headquartered in Birmingham, AL.

Vulcan Materials Co

Vulcan Materials is trending due to bullish options activity and speculation around strong construction forecasts, which could boost the company's growth. The community is focused on potential ROI from call options expiring in 2025 and 2026, with some eyeing VMC's position as a leading aggregates and concrete manufacturer. Additionally, mentions of infrastructure and building material sector strength have contributed to the increased attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal

Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.

Harmony Biosciences Holdings (HRMY) on Wednesday said that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance.Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. According to the company, the disease affects upwards of 80,000 patients in the U.S. and 121,000 patients in the European Union and the U.K. The disease is more common in males than females, but there are no FDA-approved treatments for the disorder.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-provides-update-its-phase-3-reconnect-study">said</a> on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.Shares of HRMY traded 15% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_1_01_23_PM_png_17fb739829.webp" alt="HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Chief Medical Officer Kumar Budur stated that, although the study's findings did not meet the primary endpoint, they provide valuable insights into Fragile X syndrome. “We will conduct a comprehensive analysis of the full dataset to better understand the results as part of our continued commitment to the Fragile X community,” Budur said.The trial, which enrolled 215 patients with FXS aged 3 to under 30 years, aimed to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured synthetic cannabidiol.CEO Jeffrey M. Dayno stated that the company has additional candidates in its pipeline. “We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year,” he said.HRMY stock is down by 21% this year and by 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/honda-motor-reportedly-ends-us-production-of-acura-zdx-ev/chD14gFR33x">Honda Motor Reportedly Ends US Production Of Acura ZDX EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

Equity

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.


Can Cannabis Stocks Reverse Their Prolonged Downtrend?

Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.

Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -12.82% and -1.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for

Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.

Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View

THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.

5 High Earnings Yield Stocks to Tap Into Value Investing Gains

Unlock value with IAG, PAGP, HOPE, COMM and HRMY, five stocks with high earnings yields and strong growth signals.

Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again

Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Harmony Biosciences Holdings Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$27.28
Prev Close	$26.76
Open	$26.82
Dividend Yield	0.00%
50-Day Moving Average	$34.18
Beta	0.80
Avg. Volume	1.06M
PE Ratio	8.63

52-Week High	$41.61
52-Week Low	$26.26
Market Capitalization	$1.54B
EPS (Annual)	$2.51
Price to Book	1.99
Revenue Per Employee	$2.67M
Enterprise Value/EBITDA	N/A

HRMY
Harmony Biosciences Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HRMY News

HRMY Harmony Biosciences Holdings Inc